CNS Anticancer Drug Discovery and Development Conference November 12 - 13, 2014
CNS Anticancer Drug Discovery and Development Conference November 12 - 13, 2014 Loews Hotel, Miami Beach, Florida Hosted by the Society for Neuro-Oncology The Society for Neuro-Oncology gratefully acknowledges the following sponsors for their support of this program. GOLD SILVER BRONZE Found from website recreate PMS CNS Anticancer Drug Discovery and Development Conference November 12 - 13, 2014 Loews Hotel, Miami Beach, Florida Hosted by the Society for Neuro-Oncology CONFERENCE CHAIR Victor A. Levin, MD Clinical Professor, Department of Neurosurgery, UCSF; Emeritus Professor, Department of Neuro-Oncology, UT M.D. Anderson Cancer Center; Department of Neurosurgery and Neuroscience, Kaiser Permanente ORGANIZING AND SCIENTIFIC PROGRAM COMMITTEE MEMBERS Stephen L. Eck, MD, PhD Vice President, Global Head of Medical Oncology, Astellas Pharma Global Development William Elmquist, PhD Chair, Department of Pharmaceutics, University of Minnesota James M. Gallo, PhD Professor, Dept. of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai Timothy Heffron, PhD Senior Scientist, Discovery Chemistry, Genentech Research Alan Olivero, PhD Senior Director, Discovery Chemistry, Genentech Research and Early Development Jann Sarkaria, MD Associate Professor, Department of Radiation Oncology, Mayo Clinic Beverly Teicher, PhD Chief, Molecular Pharmacology Branch, National Cancer Institute Wednesday, November 12, 2014 CNS Anticancer Drug Discovery and Development Conference 8:00am Continental Breakfast 8:30am Welcome and Introduction Victor A. Levin, MD Program Chair 8:30am - 11:55am SESSION 1: PHARMACOLOGICAL CHALLENGES 8:40am Therapy for Gliomas and Medulloblastoma: Reflection on a Life’s Work in Experimental Therapeutics and Drug Discovery/Development Victor A. Levin, MD University of California, San Francisco; Emeritus Professor, MD Anderson Cancer Center; Kaiser Permanente 9:05am Impact of Blood‐brain Barrier on Tumors and Drugs Quentin Smith, PhD Texas Tech University School of Pharmacy 9:30am Impact of Endothelial Efflux Pumps and Cellular Protective Mechanisms on Drugs William Elmquist, PhD University of Minnesota School of Pharmacy 9:50am Impact of Drug‐target Binding Kinetics on Drug Action: Principles and Practice Peter Tonge, MD, PhD Stony Brook University 10:30amBreak 10:40am AB38- The Critical Influence of the Blood‐brain Barrier (BBB) on the Success of Individualized Medicine in Glioblastoma Multiforme (GBM) Jann Sarkaria, MD Mayo Clinic 10:57am AB16- Heterogeneous Permeability, Drug Uptake, and Ffficacy in MCF7 and MDA‐MB‐231 Intracranial and Subcutaneous Xenograft Models Ramakrishna Samala, PhD Texas Tech University Health Sciences Center 11:14am Moderated Panel Discussion Moderator: Kurt Jaeckle, MD Mayo Clinic 11:55amLunch 12:45pm - 2:40pm SESSION 2: RECENT DRUG APPROACHES 12:45pm Irreversible Kinase Inhibitors in Cancer Russell Petter, PhD Celgene 1:00pm Design and Development of Reversible P13K Inhibitor Timothy Heffron, PhD Genentech, Inc. 1:20pm Design and Development of Irreversible EGFR Inhibitor Wang Shen, PhD Kanion USA, Inc. 1:35pm AB03: Discovery of PF‐06463922, a Macrocyclic Inhibitor of ALK and ROS1 Kinases with Preclinical Brain Availability and Broad Spectrum Potency Against ALK‐resistant Mutations Ted Johnson, PhD Pfizer Wednesday, November 12, 2014 CNS Anticancer Drug Discovery and Development Conference 1:50pm Large Molecule Peptide Conjugated Drugs Jean Lachowicz, PhD Angiochem, Inc. 2:10pm Moderated Panel Discussion Moderator: Alan Olivero, PhD Genentech 2:40pmBreak 2:55pm - 5:00pm SESSION 3: DRUG TARGETS AND DISCOVERY 2:55pm Functional Genomics to Identify Novel Druggable Targets in Glioblastoma Antonio Iavarone, MD Columbia University Institute for Cancer Genetics 3:15pm Next Generation Drug Discovery for Glioblastoma Using Functional Genetics, Patient Isolates, and BBB‐ Traversing “Optide” Libraries Patrick Paddison, PhD Fred Hutchinson Cancer Research Center 3:35pm Kinase Chemical Genetics and Cancer Drug Discovery Arvin Dar, PhD Icahn School of Medicine at Mount Sinai 3:55pm Proteomics for the Identification of Targets and Quantification of Therapeutic Efficacy Forest White, PhD Massachusetts Institute of Technology 4:15pm Systems Pharmacology Approaches to Inform AntiCancer Drug Discovery/Development and Personalized Therapy Marc Birtwistle, PhD Icahn School of Medicine at Mount Sinai 4:35pm Moderated Panel Discussion Moderator: Jann Sarkaria, MD Mayo Clinic 5:00pm - 7:00pm Reception Thursday, November 13, 2014 CNS Anticancer Drug Discovery and Development Conference 8:30am Continental Breakfast 9:00am - 11:15am SESSION 4: CLINICAL PATHS 9:00am Endpoints for Clinical Trials - Clinicians Perspective Patrick Wen, MD Dana-Farber Cancer Institute 9:25am Endpoints for Clinical Trials - FDA Perspective Joohee Sul, MD US Food and Drug Administration 9:50am Statistical Considerations for Single Agent and Combinations That are Relevant to Regulatory Agencies and Clinical Decision-making Donald Berry, PhD MD Anderson Cancer Center 10:30am Moderated Panel Discussion Moderator: Victor Levin, MD Patrick Wen, Joohee Sul, Donald Berry, Timothy Cloughesy and Michael Weller 11:15am - 12:30pm SESSION 5: NOVEL DRUG DELIVERY APPROACHES 11:15am AB21‐ Optimized Therapeutic Nanoparticle Delivery of Immune Modulatory MiRNA in Preclinical Murine Models of Malignancy Amy Heimberger, MD MD Anderson Cancer Center 11:27am AB49 ‐Stem Cell Based Therapies to Treat Resistant and Recurrent Brain Tumors Khalid Shah, PhD Massachusetts General Hospital/Harvard Medical School 11:39am AB51 ‐ Targeting Mitotic Kinesins to Inhibit Proliferation and Invasion of Glioblastoma Stem Cells Monica Venere, PhD Cleveland Clinic 11:51am AB34 ‐ Inhalational Therapy of NEO100 for the Treatment of Recurrent Malignant Gliomas: Upcoming Phase I/IIa Trial Thomas Chen, MD, PhD University of Southern California 12:03pm Moderated Panel Discussion Moderator: William Elmquist, PhD University of Minnesota 12:30pmLunch 1:15pm - 2:40pm 1:15pm SESSION 6: NEW AGENTS AND NOVEL TARGETS AB30 ‐ Arylsulfonamides Inhibit Glioma Growth and HIF Binding to Transcription Co‐factors P300/CBP Erwin Van Meir, PhD Winship Cancer Center, Emory University 1:27pm AB60 ‐ Genome Wide ShRNA Library Screening as a High Throughput Strategy for Discovery of Druggable Targets for Sensitizing Temozolomide in Glioblastoma Gaspar Kitange, MD, PhD Mayo Clinic Thursday, November 13, 2014 CNS Anticancer Drug Discovery and Development Conference 1:39pm AB09 ‐ Targeting Glioma‐derived Integrin Ligands as a Novel Therapeutic Approach Bozena Kaminska, PhD Nencki Institute of Experimental Biology 1:51pm AB14 ‐ Cleavage of Procaspase‐3 and Activation of Apoptosis by a Small Molecule Shows Preclinical Promise in Intracranial Models of Glioblastoma Gregory Riggins, MD, PhD Johns Hopkins University 2:03pm AB41 ‐ PENAO: a Potent Mitochondrial Targeted Inhibitor for Glioblastoma Moderator: Sylvia Chung, MSc University of New South Wales 2:15pm Moderated Panel Discussion Moderator: James Gallo, PhD Mount Sinai Medical Center 2:40pmBreak 2:50pm - 4:15pm SESSION 7: KINASE INHIBITOR AND PROTEOMICS APPROACHES TO TARGETED TREATMENTS 2:50pm AB18 ‐ Efficacy of Palbociclib, a Cdk4/6 Inhibitor, in the Treatment of Pediatric Patient‐derived Xenograft Brain Tumors Michelle Cook-Sangar, VMD, PhD Fred Hutchinson Cancer Research Center 3:02pm AB12 ‐ Bypassing Glioblastoma Resistance to EGFR Inhibitors by Synthetic Lethality Clark Chen, MD, PhD University of California, San Diego 3:14pm AB40 ‐ Activity of the GlaxoSmithKline Kinase Inhibitor Set on Glioblastoma Stem Cells Simon Khagi, MD Tufts Medical Center 3:26pm AB07 ‐Patient‐derived Xenografts Mirror the Proteomic Profile of Human Glioblastoma: Implications for Personalized Drug Development Madan Kwatra, PhD Duke University 3:38pm AB19 ‐Using a Proteomics Approach to Identify Potential Therapeutic Targets in Temozolomide‐resistant Glioblastoma Multiforme Gilberto K.K. Leung, MBBS, PhD The University of Hong Kong 3:50pm Moderated Panel Discussion Moderator: Timothy Heffron, PhD Genentech 4:15pmClosing Remarks Victor A. Levin, MD 4:20pm Adjourn Society for Neuro-Oncology 4617 Birch Street, Bellaire, TX 77401-5509 Tel: 713-349-0952 E-Fax: 832-201-8129 www.soc-neuro-onc.org
© Copyright 2024